about
Nano-Therapeutics for the Lung: State-of-the-Art and Future PerspectivesHighly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyIn vivo biocompatibility, clearance, and biodistribution of albumin vehicles for pulmonary drug deliveryPhysicochemical properties of nanoparticles regulate translocation across pulmonary surfactant monolayer and formation of lipoprotein coronaA Novel Aerosol Method for the Production of Hydrogel ParticlesComparison, synthesis and evaluation of anticancer drug-loaded polymeric nanoparticles on breast cancer cell lines.Composite glycidyl methacrylated dextran (Dex-GMA)/gelatin nanoparticles for localized protein delivery.Low cytotoxicity of solid lipid nanoparticles in in vitro and ex vivo lung models.Nanomedicine in pulmonary deliveryOptimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug deliverySafety and biocompatibility of carbohydrate-functionalized polyanhydride nanoparticles.Nanoparticles for biomedical imagingPhysicochemical characterization of nebulized superparamagnetic iron oxide nanoparticles (SPIONs).Quantum Dot-Loaded Liposomes to Evaluate the Behavior of Drug Carriers after Oral Administration.In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticlesAdvances in biomimetic regeneration of elastic matrix structures.Inter-molecular β-sheet structure facilitates lung-targeting siRNA delivery.Nanotechnology-based drug delivery systems and herbal medicines: a review.Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation.Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.Nanocarriers for pulmonary administration of peptides and therapeutic proteins.Lung vascular targeting through inhalation delivery: insight from filamentous viruses and other shapes.Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.Lipid-based carriers: manufacturing and applications for pulmonary route.Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.Pulmonary dispersion formulations: the impact of dispersed powder properties on pressurized metered dose inhaler stability.The development of models for the evaluation of pulmonary drug disposition.Nanoparticle-based therapy for respiratory diseases.Surfactant-based drug delivery systems for treating drug-resistant lung cancer.Dry powder inhalers in COPD, lung inflammation and pulmonary infections.Supercritical CO₂-Assisted Spray Drying of Strawberry-Like Gold-Coated Magnetite Nanocomposites in Chitosan Powders for Inhalation.Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.Rehydrated sterically stabilized phospholipid nanomicelles of budesonide for nebulization: physicochemical characterization and in vitro, in vivo evaluations.Bovine serum albumin adsorbed PGA-co-PDL nanocarriers for vaccine delivery via dry powder inhalation.Preparation of alginate-chitosan-cyclodextrin micro- and nanoparticles loaded with anti-tuberculosis compounds.Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension.Interactions of silica nanoparticles with lung epithelial cells and the association to flotillins.Toward an optimized treatment of intracellular bacterial infections: input of nanoparticulate drug delivery systems.Protective Effects of Liposomal N-Acetylcysteine against Paraquat-Induced Cytotoxicity and Gene Expression.
P2860
Q26786162-BDCD5B1F-8390-41BA-9D6C-49D6BB79635AQ28383844-8E7CC420-DA88-445E-8033-B6CE60A3664DQ28396006-919BF177-E00C-4A72-AD8D-B12EE72154B9Q29248541-0C1725A8-E321-4F8F-8215-C3591EC965FFQ30454598-A5DC96E1-015E-46FF-845C-619269AEAD22Q30898130-F790CBA1-95BF-4B27-8FA9-4E3E2572A3BFQ33420319-E6B0F536-2080-4F85-B6F5-52D3125B8C02Q33475063-A69B00AD-DB32-4267-B6AE-1FCA8E03E227Q33572981-6B093B5E-B04C-4186-A03A-5840E3753940Q34571360-6937FC78-4CDD-4483-9D9D-8142BE5E2DE8Q34577434-D57D4ABE-44AA-45E7-8AA5-974DA681B1ADQ34871862-4ED412AF-0B10-442A-88BF-60FB3F0D3E2DQ34989401-E284349B-1B79-4D06-80C4-7872FB08EEF3Q35200143-E729A926-76E6-4153-ADE8-2F7A10DC57ADQ35837680-AA8E1E26-EFD7-48BF-8199-E5FB8B2A9A7CQ36289257-DE041BF7-8DE0-4D1F-ADEA-8BD5429C49E8Q36552037-D4915FF4-7492-45DF-8DC0-F30A84267BAAQ36666359-527003C7-1056-47D8-B3A0-0E0FF328729DQ37391136-DE7AAA03-E6DA-4C9E-A2D6-66F0024E88B7Q37545580-06AC529B-15AE-4DE7-B2B1-31B464B7051AQ37602017-706E9312-13B8-4DB4-A430-F7120703F4F2Q37823598-D55D841A-0B2D-4583-9C3D-E50E99EAE880Q37896557-3405331B-6982-4C13-989C-911A92F1ECBBQ37978509-EA2FCB86-F339-4E65-9EEA-5E5A3A91DF7EQ38020888-6F170728-D2BA-4C16-8C3E-98FE2A1D6022Q38051096-3868268F-FF3F-4BE7-AA97-9BF22249ADDDQ38065263-EE53F895-962D-4B2D-BFA8-0696FBAD4641Q38072075-BA434926-CA65-467C-93B1-624FF1968626Q38086501-A66D6595-E63B-464B-8DA7-598957D8CB8AQ38228362-DB5896A6-2D16-4195-B349-38C3D8B3D9BDQ38267333-AF155059-FC8E-4F36-885D-9314DAF65853Q38647454-6C1E0BCB-AB26-45F8-8A64-EF69E8828914Q38789348-46693DAA-CF7E-4160-86B8-2445F32BB152Q38885341-FE3B38A9-A8A1-46D5-BDFB-F8C7E6646A05Q38949613-F53673A7-0817-4EAC-B325-9503A6B8C352Q39203063-BDD4973A-7C11-437C-BA4B-CDBF3A30221BQ39204011-E86306D1-797B-4C22-9EB5-DDE81C26FB9BQ39336533-24B6FAC1-F19D-4264-A62A-E5A27BBF971DQ40974806-9C781200-81B9-44E4-9E16-7201E9CE3FDDQ41790919-739B58A8-A14A-4D3B-A7D4-0DBC1D828B12
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nanoparticle formulations in pulmonary drug delivery.
@en
Nanoparticle formulations in pulmonary drug delivery.
@nl
type
label
Nanoparticle formulations in pulmonary drug delivery.
@en
Nanoparticle formulations in pulmonary drug delivery.
@nl
prefLabel
Nanoparticle formulations in pulmonary drug delivery.
@en
Nanoparticle formulations in pulmonary drug delivery.
@nl
P356
P1476
Nanoparticle formulations in pulmonary drug delivery.
@en
P2093
Cory J Berkland
Mark M Bailey
P304
P356
10.1002/MED.20140
P577
2009-01-01T00:00:00Z